Phaseline

Targets › RDH12

RDH12 (Retinol dehydrogenase 12): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Ophthalmology; next expected readout Dec 2032.

Retinoids dehydrogenase/reductase with a clear preference for NADP. Displays high activity towards 9-cis, 11-cis and all-trans-retinal. Shows very weak activity towards 13-cis-retinol. (UniProt, Q96NR8)

Open in Phaseline: the race on RDH12, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Opus GeneticsOPGx-RDH12
Gene therapy delivering functional RDH12 gene to retinal cells
RDH12Phase 1Leber Congenital AmaurosisDec 2032

Conditions

Leber Congenital Amaurosis (1)

Modalities

small molecule (1)

Companies

Opus Genetics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.